A Phase IIB, Multi-Center, Dose-Parallel, Randomized, Double-Blind, Monotherapy and Placebo-Controlled Safety and Efficacy Study of Zonisamide SR Plus Bupropion SR Combination Therapy in Subjects With Obesity

Trial Profile

A Phase IIB, Multi-Center, Dose-Parallel, Randomized, Double-Blind, Monotherapy and Placebo-Controlled Safety and Efficacy Study of Zonisamide SR Plus Bupropion SR Combination Therapy in Subjects With Obesity

Completed
Phase of Trial: Phase II

Latest Information Update: 23 Nov 2016

At a glance

  • Drugs Bupropion/zonisamide (Primary) ; Bupropion; Zonisamide
  • Indications Obesity
  • Focus Therapeutic Use
  • Sponsors Orexigen Therapeutics
  • Most Recent Events

    • 11 Jul 2010 Results presented at the 11th International Congress on Obesity.
    • 28 Jun 2010 Results were presented at the 70th Annual Scientific Sessions of the American Diabetes Association (ADA 2010).
    • 21 Jun 2010 Data will be presented at the American Diabetes Association 70th Scientific Sessions (Abstract 1841-P), according to an Orexigen Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top